---
company: BRAINSTORM CELL THERAPEUTICS INC.
ticker: BCLI
form: 8-K
filed: 2026-05-15
accession: 0001104659-26-062766
source: https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/
---

# Brainstorm Cell Therapeutics (BCLI) earnings release, May 15, 2026

Brainstorm Cell Therapeutics Inc. (BCLI) · Form 8-K, Item 2.02 · Filed 2026-05-15 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1137883/000110465926062766/)

BrainStorm Cell Therapeutics Announces First

Quarter 2026 Financial Results and Provides Corporate Update

NEW YORK, May 15,

2026 /PRNewswire/

-- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update.

“The team at BrainStorm is focused on completing the final steps required to initiate our planned Phase 3 ENDURANCE study of NurOwn in ALS,” said Chaim Lebovits, President and CEO.

“Site activation, manufacturing readiness, and regulatory engagement are all progressing, and, subject to securing the necessary financing, we are well positioned to move into the enrollment phase. ENDURANCE is designed to enroll patients with earlier-stage disease, where NurOwn's mechanism has the greatest opportunity to demonstrate benefit. ALS is a devastating illness with limited therapeutic options, and we remain committed to the community to complete NurOwn's development and make it available to those who need it."

Recent Highlights

NurOwn® (MSC-NTF) for ALS

Corporate

Financial Results for the Three Months Ended March 31, 2026

BRAINSTORM CELL THERAPEUTICS INC. AND

## Financial statements

### Income Statement (Three months ended — (Except share and per share amounts) (in thousands))

| | Three months ended – March 31, – 2026 – Unaudited | Three months ended – March 31, – 2025 – Unaudited |
|---|---:|---:|
| Operating expenses: | Research and development, net | 762 | 1,304 |
| Operating expenses: | General and administrative | 1,284 | 1,785 |
| Operating expenses: | Operating loss | -2,046 | -3,089 |
| Operating expenses: | Financial income (expense), net | -81 | 46 |
| Operating expenses: | Change in fair value of warrant liability |  | 179 |
| Operating expenses: | Net loss | -2,127 | -2,864 |
| Operating expenses: | Basic and diluted net loss per share | -0.19 | -0.45 |
| Operating expenses: | Weighted average number of shares outstanding used in computing basic and diluted net loss per share | 11,034,775 | 6,342,002 |

### Balance Sheet (December 31, — (Except share and per share amounts) (in thousands))

| | March 31, – 2026 – Unaudited – U.S. $ in thousands | December 31, – 2025 – Audited – U.S. $ in thousands |
|---|---:|---:|
| Current Assets: | Cash and cash equivalents | 15 | 29 |
| Current Assets: | Other accounts receivable | 122 | 86 |
| Current Assets: | Prepaid expenses and other current assets | 47 | 192 |
| Current Assets: | Total current assets | 184 | 307 |
| Long-Term Assets: | Prepaid expenses and other long-term assets | 25 | 25 |
| Long-Term Assets: | Restricted Cash | 191 | 247 |
| Long-Term Assets: | Right of use asset (Note 3) | 157 | 208 |
| Long-Term Assets: | Property and equipment, net | 198 | 235 |
| Long-Term Assets: | Total Long-Term Assets | 571 | 715 |
| Long-Term Assets: | Total assets | 755 | 1,022 |
| Current Liabilities: | Accounts payable | 7,317 | 7,067 |
| Current Liabilities: | Accrued expenses | 414 | 396 |
| Current Liabilities: | Short-term loans (Note 6) | 1,329 | 967 |
| Current Liabilities: | Operating lease liability (Note 3) | 159 | 208 |
| Current Liabilities: | Employees related liability | 2,545 | 2,369 |
| Current Liabilities: | Total current liabilities | 11,764 | 11,007 |
| Current Liabilities: | Total liabilities | 11,764 | 11,007 |
| Stockholders’ Deficit: | Stock capital: (Note 4) | 16 | 16 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Additional paid-in-capital | 228,161 | 227,058 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Treasury stock | -116 | -116 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Accumulated deficit | -239,070 | -236,943 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Total stockholders’ deficit | -11,009 | -9,985 |
| Common stock $0.00005 par value; 250,000,000 shares authorized and 11,034,775 shares issued and outstanding | Total liabilities and stockholders’ deficit | 755 | 1,022 |
